ANGPTL3 and familial hypobetalipoproteinemia 2: In general, clinical evaluations of ANGPTL3 therapeutics in normal and hyperlipidemic patients have replicated what have been observed in subjects with FHBL2, that inhibition of ANGPTL3 typically results in a reduction in HDL-C (13, 41, 42).